Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

Registration Number
NCT06496308
Lead Sponsor
Ruijin Hospital
Brief Summary

This multicenter, open-label, randomized controlled trial aims to evaluate the efficacy and safety of Orelabrutinib in combination with Bendamustine and Rituximab (OBR) versus Bendamustine and Rituximab (BR) in patients with intermediate- to high-risk mantle cell lymphoma (MCL) who are ineligible for transplantation. The primary objective is to assess the co...

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
78
Inclusion Criteria
  • Diagnosed with MCL (mantle cell lymphoma) through flow cytometry or histopathology, and has not received prior treatment.
  • Age > 18 years of age, both genders are eligible.
  • Ann Arbor stage II-IV; for stage II subjects, those who require systemic therapy based on the investigator's judgment are eligible.
  • At least one measurable lesion.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
  • Any one of the following high-risk factors is present: MIPI score of 4-11, Ki67 > 50%, TP53 abnormality, blastic or pleomorphic variation.
  • Patients who are not suitable candidates for autologous hematopoietic stem cell transplantation.
  • Laboratory tests (blood routine, liver and kidney function) meet the following requirements: a) Blood routine: White blood cell count ≥3.0×10^9/L, absolute neutrophil count ≥1.5×10^9/L, hemoglobin ≥90g/L, platelet count ≥75×10^9/L. b) Liver function: Transaminases ≤2.5 times the upper limit of normal, bilirubin ≤1.5 times the upper limit of normal. c) Serum creatinine 44-133 mmol/L.
  • The investigator judges that the subject's life expectancy is greater than 12 weeks from the time of screening.
  • Willing and able to participate in all required assessments and procedures of the study protocol.
Read More
Exclusion Criteria
  • Patients who have previously received treatment with BTK inhibitors.
  • Patients with severe complications or serious infections.
  • Patients with uncontrolled cardiovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases, etc.
  • Patients with active infections requiring systemic treatment, including bacterial, fungal, and viral infections.
  • HIV-infected individuals.
  • Patients with mental disorders or those who are known or suspected to be unable to fully comply with the study protocol.
  • Patients whom the investigator judges to have other conditions that make them unsuitable for participation in this study.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Orelabrutinib + Bendamustine + Rituximab (OBR)OrelabrutinibIn induction phase, patients will be randomized in two groups, one is OBR and another is BR. Patients in OBR group will receive rituximab 375 mg/m² IV on day 1, bendamustine 90 mg/m² IV on day 1 and 2, and orelabrutinib 150mg/day PO once daily, every 28 day per cycle for 6 cycles.
Orelabrutinib + Bendamustine + Rituximab (OBR)RituximabIn induction phase, patients will be randomized in two groups, one is OBR and another is BR. Patients in OBR group will receive rituximab 375 mg/m² IV on day 1, bendamustine 90 mg/m² IV on day 1 and 2, and orelabrutinib 150mg/day PO once daily, every 28 day per cycle for 6 cycles.
Orelabrutinib + Bendamustine + Rituximab (OBR)BendamustineIn induction phase, patients will be randomized in two groups, one is OBR and another is BR. Patients in OBR group will receive rituximab 375 mg/m² IV on day 1, bendamustine 90 mg/m² IV on day 1 and 2, and orelabrutinib 150mg/day PO once daily, every 28 day per cycle for 6 cycles.
Bendamustine + Rituximab (BR)BendamustineIn induction phase, patients will be randomized in two groups, one is OBR and another is BR. Patients in BR group will receive rituximab 375 mg/m² IV on day 1, bendamustine 90 mg/m² IV on day 1 and 2, every 28 day per cycle for 6 cycles.
Orelabrutinib + Venetoclax (OV)VenetoclaxIn maintanance phase, patients will receive different medical regimen according to their TP53 mutation and blastic and pleomorphic variants status. Patients with TP53 mutation or blastic and/or pleomorphic variant will receive orelabrutinib 150mg/day PO once daily and venetoclax for up to 2 years, the dosing of Venetoclax is escalated gradually to reach a target dose of 400 mg.
Orelabrutinib (O)OrelabrutinibIn maintanance phase, patients will receive different medical regimen according to their TP53 mutation and blastic and pleomorphic variants status. Patients without TP53 mutation or blastic and/or pleomorphic variant will receive orelabrutinib 150mg/day PO once daily for up to 2 years.
Bendamustine + Rituximab (BR)RituximabIn induction phase, patients will be randomized in two groups, one is OBR and another is BR. Patients in BR group will receive rituximab 375 mg/m² IV on day 1, bendamustine 90 mg/m² IV on day 1 and 2, every 28 day per cycle for 6 cycles.
Orelabrutinib + Venetoclax (OV)OrelabrutinibIn maintanance phase, patients will receive different medical regimen according to their TP53 mutation and blastic and pleomorphic variants status. Patients with TP53 mutation or blastic and/or pleomorphic variant will receive orelabrutinib 150mg/day PO once daily and venetoclax for up to 2 years, the dosing of Venetoclax is escalated gradually to reach a target dose of 400 mg.
Primary Outcome Measures
NameTimeMethod
Complete response rateEnd of induction treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=28 days]

Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

Secondary Outcome Measures
NameTimeMethod
Overall Response RateEnd of induction treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=28 days]

Percentage of participants with overall response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

Overall survivalBaseline up to data cut-off (up to approximately 2 years)

Overall survival was defined as the time from the date of randomization to the date of death from any cause.

Progression-free survivalBaseline up to data cut-off (up to approximately 2 years)

Progression-free survival was defined as the time from the date of randomization until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.

Trial Locations

Locations (1)

Ruijin Hospital

🇨🇳

Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath